Tiara D Aldridge1, Katherine E Hartmann, Kara A Michels, Digna R Velez Edwards. 1. Vanderbilt Epidemiology Center, Nashville, TN, USA; Vanderbilt University, Institute of Medicine and Public Health, Nashville, TN, USA; Vanderbilt University, Department of Obstetrics and Gynecology, Nashville, TN, USA.
Abstract
PURPOSE: We tested whether antihistamine exposure during early pregnancy is associated with spontaneous abortion (SAB) or preterm birth (PTB). METHODS: Women were enrolled in Right from the Start (2004-2010), a prospective pregnancy cohort. Data about first-trimester antihistamine use were obtained from screening and first-trimester interviews. Self-reported outcomes included SAB and PTB and were verified by medical records. Cox proportional hazards models were used to test for an association between antihistamine use and each outcome, both performed adjusting for confounders. RESULTS: Among the 2685 pregnancies analyzed, 14% (n = 377) reported use of antihistamines. Among antihistamine users, 12% (n = 44) experienced SABs, and 6% (n = 21) had PTBs. Antihistamine exposure was not associated with SAB (adjusted hazard ratio [aHR] = 0.88, 95% confidence interval [CI] 0.64, 1.21) or PTB, which was modified by maternal race (aHR = 1.03, 95%CI 0.61, 1.72 among White women and aHR = 0.43, 95%CI 0.14, 1.34 among Black women). CONCLUSIONS: Despite the biologic plausibility that antihistamine use may influence pregnancy outcomes, we did not detect evidence of an association with SAB or PTB. These data demonstrate the utility of large prospective cohorts for evaluating drug safety in pregnancy when concerns are raised from animal models.
PURPOSE: We tested whether antihistamine exposure during early pregnancy is associated with spontaneous abortion (SAB) or preterm birth (PTB). METHODS:Women were enrolled in Right from the Start (2004-2010), a prospective pregnancy cohort. Data about first-trimester antihistamine use were obtained from screening and first-trimester interviews. Self-reported outcomes included SAB and PTB and were verified by medical records. Cox proportional hazards models were used to test for an association between antihistamine use and each outcome, both performed adjusting for confounders. RESULTS: Among the 2685 pregnancies analyzed, 14% (n = 377) reported use of antihistamines. Among antihistamine users, 12% (n = 44) experienced SABs, and 6% (n = 21) had PTBs. Antihistamine exposure was not associated with SAB (adjusted hazard ratio [aHR] = 0.88, 95% confidence interval [CI] 0.64, 1.21) or PTB, which was modified by maternal race (aHR = 1.03, 95%CI 0.61, 1.72 among White women and aHR = 0.43, 95%CI 0.14, 1.34 among Black women). CONCLUSIONS: Despite the biologic plausibility that antihistamine use may influence pregnancy outcomes, we did not detect evidence of an association with SAB or PTB. These data demonstrate the utility of large prospective cohorts for evaluating drug safety in pregnancy when concerns are raised from animal models.
Authors: A Ruigómez; L A García Rodríguez; C Cattaruzzi; M G Troncon; L Agostinis; M A Wallander; S Johansson Journal: Am J Epidemiol Date: 1999-09-01 Impact factor: 4.897
Authors: S J Hill; C R Ganellin; H Timmerman; J C Schwartz; N P Shankley; J M Young; W Schunack; R Levi; H L Haas Journal: Pharmacol Rev Date: 1997-09 Impact factor: 25.468
Authors: Jocelyn N Pennefather; Eva Patak; Sebastian Ziccone; Alison Lilley; Francisco M Pinto; Nigel M Page; Margot E Story; Sonia Grover; M Luz Candenas Journal: Biol Reprod Date: 2006-05-17 Impact factor: 4.285